TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23701521

Group type: EXPERIMENTAL
Intervention: Microneedles + iontophoresis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Iontophoresis alone
Number of subjects: 12
Study: 21788625

Group type: EXPERIMENTAL
Intervention: Soy germ pasta (one serving/day for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional pasta (one serving/day for 8 weeks)
Number of subjects: 0
Study: 19105577

Group type: EXPERIMENTAL
Intervention: Experimental condition (orthographically similar)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semantic association task (experimental condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vowel counting task (experimental condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (orthographically dissimilar)
Number of subjects: 0
Study: 16472987

Group type: EXPERIMENTAL
Intervention: 600 mg clindamycin
Number of subjects: 150

Group type: COMPARATOR
Intervention: 2 g phenethicillin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups (clindamycin and phenethicillin)
Number of subjects: 150
Study: 12882677

Group type: EXPERIMENTAL
Intervention: Arthrowand technique under arthroscope
Number of subjects: 72

Group type: COMPARATOR
Intervention: Knee arthroscope (control group)
Number of subjects: 72
Study: 10728957

Group type: EXPERIMENTAL
Intervention: Oral glycoprotein IIb‐IIIa inhibitor orbofiban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9194208

Group type: EXPERIMENTAL
Intervention: Bucillamine
Number of subjects: 46

Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 46
Study: 1539881

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine solutions prepared seven days, one day, and just before use
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 24
Study: 3895175

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional therapy (ampicillin and chloramphenicol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 50
Study: 31382653

Group type: EXPERIMENTAL
Intervention: Minimum dietary diversity (MDD) consumption (≥4/8 items)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Consumption of animal source foods
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Consumption of vegetables/fruits
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Consumption of processed foods
Number of subjects: 305
Study: 29633302

Group type: EXPERIMENTAL
Intervention: Efavirenz tablets (test product) in females
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Efavirenz tablets (test product) in males
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Efavirenz tablets (test product) in females (pivotal study)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Efavirenz tablets (test product) in males (pivotal study)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comparison of test/reference ratio in pilot study
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comparison of test/reference ratio in pivotal study
Number of subjects: 48
Study: 27369111

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4)
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg every 4 weeks (Rq4)
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks (2q8)
Number of subjects: 1815
Study: 25171023

Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 148
Study: 22487001

Group type: EXPERIMENTAL
Intervention: Parnaparin 8500 UI once daily for 10 days followed by placebo for 20 days (group A)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Parnaparin 8500 UI once daily for 10 days followed by 6400 UI once daily for 20 days (group B)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Parnaparin 4250 UI once daily for 30 days (group C)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Comparison of group B vs. group A
Number of subjects: 664

Group type: COMPARATOR
Intervention: Comparison of group B vs. group C
Number of subjects: 664

Group type: COMPARATOR
Intervention: Comparison of group C vs. group A
Number of subjects: 664

Group type: COMPARATOR
Intervention: Group A
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: No major hemorrhages occurred.
Number of subjects: 664
Study: 20517641

Group type: EXPERIMENTAL
Intervention: Buspirone (0.5 mg/kg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Methylphenidate (0.3-1 mg/kg/day)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 34
Study: 17613851

Group type: EXPERIMENTAL
Intervention: Free examination
Number of subjects: 484

Group type: COMPARATOR
Intervention: Standard (pay) examination
Number of subjects: 484
Study: 15127961

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Ondansetron 32 mg
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Granisetron (10 microg/kg or 1 mg)
Number of subjects: 224
Study: 11961610

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (GBP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Open gastric bypass (GBP)
Number of subjects: 51
Study: 9447512

Group type: EXPERIMENTAL
Intervention: Unreamed intramedullary nailing (IMN)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Half-pin external fixators (EF)
Number of subjects: 168
Study: 7646913

Group type: EXPERIMENTAL
Intervention: Subcapsular orchiectomy plus oral hydrocortisone and bromocriptine (arm 3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subcapsular orchiectomy alone (arm 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subcapsular orchiectomy plus flutamide (arm 2)
Number of subjects: 30
Study: 2676529

Group type: EXPERIMENTAL
Intervention: Oral controlled-release morphine (30 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 349776

Group type: EXPERIMENTAL
Intervention: Toothpaste 'Silka' with circulation-stimulation additives
Number of subjects: 0
Study: 31129665

Group type: EXPERIMENTAL
Intervention: Monopolar hysteroscopic surgery using a mixture of 2.7% sorbitol and 0.54% mannitol (HSMP group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Bipolar hysteroscopic surgery using 0.9% isotonic saline (HSBP group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (HSMP and HSBP)
Number of subjects: 54
Study: 28829792

Group type: EXPERIMENTAL
Intervention: Endurance exercise for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-exercised control group
Number of subjects: 23
Study: 25483694

Group type: EXPERIMENTAL
Intervention: Bivalent Staphylococcus aureus glycoconjugated vaccine (2 doses)
Number of subjects: 3359

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3359
Study: 23400901

Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Bayesian estimator
Number of subjects: 76
Study: 21860342

Group type: EXPERIMENTAL
Intervention: Low dose MDMA (1.0 mg/kg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High dose MDMA (1.6 mg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MDMA detection
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MDA detection
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MDMA detection window
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MDA detection window
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MDMA positive rates
Number of subjects: 29
Study: 19246703

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 16100299

Group type: EXPERIMENTAL
Intervention: Vinpocetine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11833048

Group type: EXPERIMENTAL
Intervention: 75 g sucrose with a moderate fat load
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 75 g glucose with a moderate fat load
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Increased risk group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 10084100

Group type: EXPERIMENTAL
Intervention: 1 microgram kg-1 clonidine
Number of subjects: 36

Group type: COMPARATOR
Intervention: 30 micrograms kg-1 morphine
Number of subjects: 36
Study: 8977623

Group type: EXPERIMENTAL
Intervention: Methanol vapor exposure at 200 ppm for 4 hours
Number of subjects: 26

Group type: COMPARATOR
Intervention: Water vapor exposure (control)
Number of subjects: 26
Study: 2149995

Group type: EXPERIMENTAL
Intervention: estramustine
Number of subjects: 72

Group type: COMPARATOR
Intervention: mitomycin
Number of subjects: 72
Study: 10246465

Group type: EXPERIMENTAL
Intervention: Pamphlet delivery method
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pamphlet and nurse visit delivery method
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nurse visit delivery method
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no preoperative information)
Number of subjects: 50
Study: 30359062

Group type: EXPERIMENTAL
Intervention: Imagining restricted future time perspective
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imagining expansive future time perspective
Number of subjects: 0

Group type: COMPARATOR
Intervention: No instructions
Number of subjects: 0
Study: 29029896

Group type: EXPERIMENTAL
Intervention: Clemastine fumarate (5·36 mg orally twice daily) for 90 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 90 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clemastine fumarate (5·36 mg orally twice daily) for 60 days
Number of subjects: 50
Study: 25545446

Group type: EXPERIMENTAL
Intervention: Broad-spectrum light (BSL) phototherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blue LED phototherapy
Number of subjects: 40
Study: 23415431

Group type: EXPERIMENTAL
Intervention: Hazelnut-enriched diet (4 weeks; hazelnut contributing 18%-20% of total daily energy intake)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hazelnut-enriched diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control diet I (4 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control diet II (4 weeks)
Number of subjects: 21
Study: 21240901

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 15 μg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19594841

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin-A (BoNT-A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 17523268

Group type: EXPERIMENTAL
Intervention: Biliary drainage through the cystic duct
Number of subjects: 40

Group type: COMPARATOR
Intervention: Biliary drainage through the other procedure (not specified)
Number of subjects: 40
Study: 15355147

Group type: EXPERIMENTAL
Intervention: High school students
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: American participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chinese participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants who did not report being reminded of the source tale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Similarity of solution tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Similarity of goal object
Number of subjects: 0
Study: 11685343

Group type: EXPERIMENTAL
Intervention: ASPIDS with respiratory rate (RR) of 14 min(‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: ASPIDS with respiratory rate (RR) of 20 min(‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: ASPIDS
Number of subjects: 7
Study: 9481031

Group type: EXPERIMENTAL
Intervention: Cod liver oil (10 mL daily)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Corn oil (10 mL daily)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Maternal plasma leptin concentration
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Maternal plasma leptin concentration for female fetuses
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Maternal plasma leptin concentration for male fetuses
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Plasma leptin concentration at birth (umbilical cord plasma)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Plasma leptin concentration at 4 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Plasma leptin concentration at 14 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Plasma leptin levels at 4 and 14 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Plasma leptin concentration increase from 4 to 14 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Leptin concentration in umbilical cord plasma
Number of subjects: 180
Study: 7817456

Group type: EXPERIMENTAL
Intervention: Vitamin A and megadose multivitamins in combination with intravesical BCG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KLH (keyhole limpet hemocyanin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mistletoe extracts or intravesical antineoplastic iontophoresis
Number of subjects: 0
Study: 2918185

Group type: EXPERIMENTAL
Intervention: Theophylline and enprofylline
Number of subjects: 29

Group type: COMPARATOR
Intervention: Antigen
Number of subjects: 29

Group type: COMPARATOR
Intervention: Compound 48/80
Number of subjects: 29

Group type: COMPARATOR
Intervention: Antigen vs Compound 48/80
Number of subjects: 29
Study: 803187

Group type: EXPERIMENTAL
Intervention: Fluphenazine/nortriptyline (F/N)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 72
Study: 29106053

Group type: EXPERIMENTAL
Intervention: Fosdagrocorat (PF-04171327)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 0
Study: 28699563

Group type: EXPERIMENTAL
Intervention: Intervention clusters (CASCADA intervention)
Number of subjects: 6185

Group type: EXPERIMENTAL
Intervention: Female intervention responses
Number of subjects: 6185

Group type: EXPERIMENTAL
Intervention: Male intervention responses
Number of subjects: 6185

Group type: COMPARATOR
Intervention: Control clusters
Number of subjects: 6185

Group type: COMPARATOR
Intervention: Female control respondents
Number of subjects: 6185

Group type: COMPARATOR
Intervention: Male control respondents
Number of subjects: 6185
Study: 26143444

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) plus peginterferon alfa‐2a (PegIFN) for 48 weeks
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: TDF plus PegIFN for 16 weeks followed by TDF for 32 weeks
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: PegIFN for 48 weeks
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: TDF for 120 weeks
Number of subjects: 737

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 737
Study: 23269313

Group type: EXPERIMENTAL
Intervention: Endoscopic biliary stenting
Number of subjects: 164
Study: 20844893

Group type: EXPERIMENTAL
Intervention: Preoperative endoscopic sphincterotomy followed by laparoscopic cholecystectomy (PES/LC)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy combined with intraoperative endoscopic sphincterotomy (LC/IOES)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (PES/LC)
Number of subjects: 198
Study: 18720890

Group type: EXPERIMENTAL
Intervention: Trained volunteer-delivered mental health support
Number of subjects: 102

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 102
Study: 17361529

Group type: EXPERIMENTAL
Intervention: Conventional Western medicine plus Xin'anning Nasal Drop (XAND)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 60
Study: 12598392

Group type: EXPERIMENTAL
Intervention: Intervention group received videotapes and a brochure designed to review skills for self control and treatment
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group received a videotape and brochure with general diabetes information
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group received traditional treatment only
Number of subjects: 332
Study: 10538257

Group type: EXPERIMENTAL
Intervention: Screening CT scans within 24 hours of admission
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CT studies at physician's discretion)
Number of subjects: 22
Study: 8671551

Group type: EXPERIMENTAL
Intervention: Espresso (E)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Mocha (M)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Tea (T)
Number of subjects: 84
Study: 1817621

Group type: EXPERIMENTAL
Intervention: 5 cm H2O CPAP via a nasal mask
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 2.5 cm H2O CPAP via a nasal mask
Number of subjects: 150

Group type: COMPARATOR
Intervention: 0 cm H2O CPAP (Control)
Number of subjects: 150
Study: 7040657

Group type: EXPERIMENTAL
Intervention: Saline flush following diazepam administration
Number of subjects: 500

Group type: COMPARATOR
Intervention: Barbotage (diluting the drug with the patient's own blood before injection)
Number of subjects: 500
Study: 31035117

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel (8%, 90 mg) once daily
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Intramuscular progesterone (progesterone oil) once daily
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Intramuscular progesterone
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel and Intramuscular progesterone
Number of subjects: 1313
Study: 28114711

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control Group (KG)
Number of subjects: 57
Study: 26505104

Group type: EXPERIMENTAL
Intervention: science-causal explanations (SC)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: clinical concepts before basic science (CB)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: clinical features list only (FL)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: basic science before clinical concepts (BC)
Number of subjects: 94
Study: 23830936

Group type: EXPERIMENTAL
Intervention: Once-weekly resistance training (1x RT)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training (2x RT)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Twice-weekly balance and tone training (BAT)
Number of subjects: 155
Study: 22137075

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d) with cilostazol (200 mg/d) for 14 days (group 3)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d) for 14 days (group 1)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: High-maintenance dose of clopidogrel (150 mg/d) for 14 days (group 2)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/d) for 14 days (control group)
Number of subjects: 74
Study: 19232828

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB)
Number of subjects: 42
Study: 17971943

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg/d for 48 weeks
Number of subjects: 210

Group type: COMPARATOR
Intervention: Diammonium glycyrrhizinate
Number of subjects: 210

Group type: COMPARATOR
Intervention: Diammonium glycyrrhizinate alone
Number of subjects: 210
Study: 15006963

Group type: EXPERIMENTAL
Intervention: Single-breath DLNO measurements (inspired nitric oxide concentration, 66.5 ± 10.6 ppm)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Single-breath DLNO measurements at rest and at 90% VO(2)R
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Stepwise regression analysis of DLNO
Number of subjects: 8
Study: 11791956

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) 25 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ) 15 mg/kg
Number of subjects: 0
Study: 10930676

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza vaccine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Unadjuvanted subunit influenza vaccine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9065352

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (256 micrograms/day)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (400 micrograms/day)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Budesonide pMDI (400 micrograms/day)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 8417382

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 106

Group type: COMPARATOR
Intervention: No calcium-channel blocker
Number of subjects: 106
Study: 3786479

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30055891

Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy without impaction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy with impaction
Number of subjects: 20
Study: 29926695

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) at 120 seconds after birth
Number of subjects: 100

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) and Immediate cord clamping (ICC)
Number of subjects: 100
Study: 24530676

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 4432
Study: 22228743

Group type: EXPERIMENTAL
Intervention: α-lipoic acid (ALA) 600 mg once daily for 5 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 20337981

Group type: EXPERIMENTAL
Intervention: Early enteral feeding starting within 24 hours of birth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Number of subjects: 0